Management of Drug Interactions Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Management of Drug Interactions. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Management of Drug Interactions Indian Medical PG Question 1: Why is a regimen of four drugs recommended for a TB patient on the first visit?
- A. To prevent emergence of drug-resistant strains (Correct Answer)
- B. To reduce bacterial load effectively
- C. To minimize treatment duration
- D. None of the options
Management of Drug Interactions Explanation: ***To prevent emergence of drug-resistant strains***
- Using a **four-drug regimen** at the initial stage significantly reduces the likelihood of **Mycobacterium tuberculosis** developing resistance to any single drug.
- This strategy ensures that even if a small number of bacteria are naturally resistant to one drug, the other drugs will still be effective in killing them, preventing the proliferation of **resistant strains**.
*To minimize treatment duration*
- While a multi-drug regimen is effective, its primary goal is not to minimize treatment duration but rather to ensure **eradication of the infection** and prevent resistance.
- Treatment duration is determined by the need to kill both actively multiplying and dormant bacteria, which typically takes several months even with multiple drugs.
*To reduce bacterial load effectively*
- Reducing bacterial load is certainly a goal of TB treatment, but the use of four drugs is specifically aimed at achieving this while simultaneously preventing **drug resistance**.
- A single effective drug could reduce bacterial load, but it would quickly lead to the emergence of resistant bacteria, making the long-term goal of **cure** impossible.
*None of the options*
- This option is incorrect because the primary reason for a **four-drug regimen** in TB treatment is indeed to prevent the emergence of **drug-resistant strains**.
Management of Drug Interactions Indian Medical PG Question 2: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Management of Drug Interactions Explanation: ***Zero order kinetics***
- This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time.
- Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses.
*First pass kinetics*
- This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration.
- While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses.
*First order kinetics*
- In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration.
- Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated.
*Second order kinetics*
- This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants.
- It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Management of Drug Interactions Indian Medical PG Question 3: In patients taking tadalafil, the most serious drug interaction occurs with:
- A. Alpha-Blockers
- B. Ketoconazole
- C. Rifampicin
- D. Nitrates (Correct Answer)
Management of Drug Interactions Explanation: ***Nitrates***
- The co-administration of **tadalafil** (a PDE5 inhibitor) with **nitrates** can cause a dangerous and potentially fatal drop in **blood pressure**.
- Both drug classes lead to increased cGMP levels, resulting in excessive **vasodilation** and profound **hypotension**.
*Alpha-Blockers*
- Alpha-blockers, while able to cause **hypotension** when taken with tadalafil, generally lead to less severe interactions than nitrates.
- The combination requires caution and potentially dose adjustments, but typically does not result in the same life-threatening blood pressure drops as seen with nitrates.
*Ketoconazole*
- **Ketoconazole** is a strong **CYP3A4 inhibitor**, which can increase the plasma concentration of tadalafil.
- This interaction can potentiate tadalafil's effects and increase the risk of side effects, but it doesn't create an immediate, life-threatening hypotensive crisis like nitrates.
*Rifampicin*
- **Rifampicin** is a potent **CYP3A4 inducer**, which can significantly decrease the plasma concentration of tadalafil.
- This interaction primarily leads to a **reduced efficacy** of tadalafil, rather than a dangerous increase in adverse effects or a severe drug-drug interaction.
Management of Drug Interactions Indian Medical PG Question 4: Which of the following statements represents the most clinically significant aspect of drug metabolism?
- A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
- B. Glucuronidation is a phase II reaction
- C. Reduction is a phase I reaction
- D. Cytochrome P450 is involved in phase I reactions
Management of Drug Interactions Explanation: ***Most common enzyme involved is Cyp 3A4/5***
- CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**.
- Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity.
*Glucuronidation is a phase II reaction*
- While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5.
- Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone.
*Reduction is a phase I reaction*
- This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**.
- However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism.
*Cytochrome P450 is involved in phase I reactions*
- This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive.
- While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.
Management of Drug Interactions Indian Medical PG Question 5: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
- A. decreased renal excretion of drugs
- B. decreased hepatic metabolism
- C. decreased volume of distribution (Correct Answer)
- D. increased receptor sensitivity
Management of Drug Interactions Explanation: ***decreased volume of distribution***
- A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**.
- However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs.
*decreased renal excretion of drugs*
- **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance.
- This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**.
*decreased hepatic metabolism*
- Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age.
- This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations.
*increased receptor sensitivity*
- Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs.
- This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.
Management of Drug Interactions Indian Medical PG Question 6: A 75-year-old male on warfarin is prescribed an antibiotic for pneumonia. Which antibiotic requires INR monitoring due to increased bleeding risk?
- A. Ciprofloxacin (Correct Answer)
- B. Amoxicillin
- C. Clindamycin
- D. Azithromycin
Management of Drug Interactions Explanation: ***Ciprofloxacin***
- **Ciprofloxacin** and other fluoroquinolones can interact with **warfarin**, though the mechanism is **not well-established** and likely multifactorial (may involve gut flora disruption, protein binding displacement, or metabolic effects).
- This interaction can lead to **increased INR** and bleeding risk, requiring close monitoring.
- Among fluoroquinolones, the interaction is **less predictable** compared to some other antibiotics.
*Amoxicillin*
- **Amoxicillin** and other beta-lactam antibiotics can interact with warfarin through **gut flora disruption**, reducing vitamin K synthesis.
- This can lead to increased INR, though the effect is generally **mild to moderate**.
- Routine INR monitoring is typically sufficient without intensive monitoring.
*Clindamycin*
- **Clindamycin** has **minimal documented interaction** with warfarin.
- It does not significantly affect warfarin metabolism or vitamin K synthesis.
- Generally considered a **safer option** for patients on warfarin therapy.
*Azithromycin*
- **Azithromycin** is well-documented to **significantly increase INR** and bleeding risk in patients on warfarin.
- The mechanism may involve **CYP3A4 effects** and other pharmacokinetic interactions.
- **FDA warnings exist** regarding this interaction, and close INR monitoring is essential.
- Note: While this option is also clinically significant, the question focuses on identifying ONE antibiotic requiring monitoring, with ciprofloxacin being the presented answer in this educational context.
Management of Drug Interactions Indian Medical PG Question 7: A patient who was diagnosed with epilepsy was put on retigabine TDS. Now phenytoin is being added. Which of the following changes should be made to retigabine?
- A. Stop the drug
- B. Stop retigabine and start on carbamazepine
- C. Increase the dose (Correct Answer)
- D. Decrease the dose
Management of Drug Interactions Explanation: ***Increase the dose***
- **Phenytoin** is a potent **enzyme inducer** that induces hepatic enzymes including **UGT (glucuronidation) enzymes**.
- **Retigabine** is primarily metabolized by **N-acetylation and glucuronidation** (not significantly by CYP450 enzymes).
- Phenytoin induces UGT enzymes, which **increases retigabine metabolism and clearance**, leading to **decreased plasma concentrations**.
- To maintain therapeutic levels and seizure control, the **dose of retigabine needs to be increased** when co-administered with phenytoin.
*Stop the drug*
- There is no clinical indication to completely **stop retigabine** simply because phenytoin is being added, as both can be used concurrently with dose adjustment.
- Doing so might lead to a **loss of seizure control** if retigabine was providing effective seizure management.
*Stop retigabine and start on carbamazepine*
- This is an unnecessary and unindicated change; there is no medical reason to **switch from retigabine to carbamazepine** due to phenytoin addition.
- Like phenytoin, **carbamazepine is also a strong enzyme inducer**, so similar drug interactions would occur.
*Decrease the dose*
- **Decreasing the dose** would be appropriate if phenytoin were an enzyme inhibitor, leading to higher retigabine levels.
- Since phenytoin is an **enzyme inducer**, decreasing the dose would further reduce retigabine's therapeutic concentration, potentially leading to **breakthrough seizures**.
Management of Drug Interactions Indian Medical PG Question 8: Which of the following best describes a Type B adverse drug reaction?
- A. Augmented effect of drug
- B. Effect seen on chronic use of drug
- C. Delayed effect of drug
- D. Unpredictable bizarre reaction (Correct Answer)
Management of Drug Interactions Explanation: ***Unpredictable bizarre reaction***
- Type B reactions are **unpredictable**, **bizarre**, and not directly related to the drug's known pharmacological actions.
- They often involve **immunological reactions** or genetic predispositions, such as allergies or idiosyncratic responses.
*Augmented effect of drug*
- This describes a **Type A** adverse drug reaction, which is predictable and results from an **exaggerated pharmacological effect** of the drug.
- It is typically dose-dependent and can be managed by adjusting the dosage.
*Effect seen on chronic use of drug*
- This description can apply to several types of adverse reactions, but it commonly relates to **Type C (chronic) reactions**, where effects occur only after prolonged exposure.
- These reactions might be due to **cumulative toxicity** or adaptive changes in the body.
*Delayed effect of drug*
- This aligns with **Type D (delayed) adverse drug reactions**, which manifest long after the drug exposure has ended or after a period of latency.
- Examples include **carcinogenesis** or teratogenesis, occurring months or years later.
Management of Drug Interactions Indian Medical PG Question 9: Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?
- A. Amoxicillin
- B. Cefotaxime
- C. Erythromycin (Correct Answer)
- D. Cotrimoxazole
Management of Drug Interactions Explanation: ***Erythromycin***
- **Erythromycin**, a macrolide antibiotic, is a potent inhibitor of the **cytochrome P450 (CYP450) enzyme system**, specifically **CYP1A2**, which is the primary enzyme responsible for theophylline metabolism.
- Co-administration of erythromycin can significantly **increase theophylline levels**, leading to toxicity such as **nausea, vomiting, seizures, or cardiac arrhythmias.**
- This interaction is clinically significant and erythromycin should be avoided in patients on theophylline therapy.
*Amoxicillin*
- **Amoxicillin** is a penicillin-class antibiotic that has minimal interaction with theophylline metabolism.
- It does not significantly inhibit the **CYP1A2 enzyme** and is generally considered safe to use with theophylline.
*Cefotaxime*
- **Cefotaxime**, a third-generation cephalosporin, does not significantly affect the metabolism of theophylline.
- It does not inhibit **CYP1A2 enzymes** and is safe for use in patients on theophylline therapy.
*Cotrimoxazole*
- **Cotrimoxazole** (trimethoprim/sulfamethoxazole) may slightly increase theophylline levels by inhibiting some CYP450 isoenzymes, but its effect is generally less pronounced than that of erythromycin.
- While caution and monitoring are advised, it is not as strongly contraindicated as erythromycin due to a lower risk of significant toxicity in most cases.
Management of Drug Interactions Indian Medical PG Question 10: Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?
- A. Indinavir
- B. Ritonavir (Correct Answer)
- C. Lamivudine
- D. Efavirenz
Management of Drug Interactions Explanation: ***Ritonavir (Correct Answer)***
- **Ritonavir** is the most critical drug to avoid due to severe drug-drug interactions with **rifampicin**
- **Rifampicin** is a potent CYP3A4 inducer that dramatically reduces ritonavir plasma concentrations by 75-90%, rendering it completely ineffective
- Ritonavir is commonly used as a pharmacokinetic booster for other protease inhibitors, making this interaction particularly significant
- **Contraindicated** with rifampicin-based TB regimens
*Indinavir*
- Also a protease inhibitor metabolized via CYP3A4
- Should also be **avoided with rifampicin** as levels are reduced by approximately 90%
- However, indinavir is rarely used in modern ART regimens due to high pill burden, need for dietary restrictions, and significant side effects (nephrolithiasis)
- Less commonly used than ritonavir, making ritonavir the better answer
*Lamivudine*
- Nucleoside reverse transcriptase inhibitor (NRTI) with **renal elimination**
- Not metabolized by CYP450 enzymes
- **No significant interactions** with rifampicin or other anti-TB drugs
- Safe and commonly used in TB/HIV co-infection
*Efavirenz*
- Non-nucleoside reverse transcriptase inhibitor (NNRTI) that **can be safely co-administered** with rifampicin
- Standard dose (600 mg daily) is generally adequate, though some guidelines recommend considering 800 mg in patients >60 kg
- **Preferred NNRTI** for TB/HIV co-infection according to WHO guidelines
- Well-studied and effective combination with rifampicin-based TB therapy
More Management of Drug Interactions Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
oka